Clearstead Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Clearstead Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9	Closed	-$41	–	3268
2025 Q2	$41	Buy	+9	New	+$40	﹤0.01%	2684

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Clearstead Advisors's YMAB Position: Q3 2025 in Review

Clearstead Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 9 shares — an estimated $41 sold.

Clearstead Advisors first reported a position in YMAB in Q2 2025 and held it in 1 quarter. The position peaked at $41 in Q2 2025. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Clearstead Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Clearstead Advisors sold 9 Y-mAbs Therapeutics shares in Q3 2025, an estimated $41.
Clearstead Advisors first reported a position in Y-mAbs Therapeutics in Q2 2025 and held it in 1 quarter.
Clearstead Advisors's Y-mAbs Therapeutics position peaked at $41 in Q2 2025.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.